Literature DB >> 17346187

The IGF-I axis in thyroid carcinoma.

A Ciampolillo1, C De Tullio, E Perlino, E Maiorano.   

Abstract

Insulin like-growth factor I (IGF-I) has been involved in the pathogenesis of a variety of human neoplasia due to the mitogenic and anti-apoptotic properties of its cognate receptor. In human thyroid carcinomas, we have previously documented an increased immunoreactivity of both IGF-I and the IGF-I receptor (IGF-I R) associated with up regulation of IGF-I mRNA . Immunoreactivity of IGF-I and cognate receptor positively correlated with tumor diameter and wide intrathyroidal extension but not with patient's gender and age or with the stage of the tumors and the occurrence of limph node metastases. Most experimental studies indicate that the effects of IGF-I on target cells are regulated in a complex fashion and depend on the simultaneous occurrence of IGF-IR and the binding proteins.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17346187     DOI: 10.2174/138161207780249209

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  13 in total

1.  The relationship between glucose metabolism disorders and malignant thyroid disease.

Authors:  Ayse Ocak Duran; Cüneyd Anil; Alptekin Gursoy; Aslı Nar; Ozden Altundag; Neslihan Bascil Tutuncu
Journal:  Int J Clin Oncol       Date:  2012-06-30       Impact factor: 3.402

2.  Sequence-specific targeting of IGF-I and IGF-IR genes by camptothecins.

Authors:  Kahina Oussedik; Jean-Christophe François; Ludovic Halby; Catherine Senamaud-Beaufort; Géraldine Toutirais; Sabrina Dallavalle; Yves Pommier; Claudio Pisano; Paola B Arimondo
Journal:  FASEB J       Date:  2010-02-23       Impact factor: 5.191

3.  The relationship between thyroid volume and malignant thyroid disease.

Authors:  Ayse Ocak Duran; Cuneyd Anil; Alptekin Gursoy; Aslı Nar; Ozden Altundag; Mevlude Inanc; Oktay Bozkurt; Neslihan Bascil Tutuncu
Journal:  Med Oncol       Date:  2013-12-12       Impact factor: 3.064

4.  TSH compensates thyroid-specific IGF-I receptor knockout and causes papillary thyroid hyperplasia.

Authors:  Kathrin Müller; Dagmar Führer; Jens Mittag; Nora Klöting; Matthias Blüher; Roy E Weiss; Marie-Christine Many; Kurt Werner Schmid; Knut Krohn
Journal:  Mol Endocrinol       Date:  2011-10-06

5.  Health disparities in endocrine disorders: biological, clinical, and nonclinical factors--an Endocrine Society scientific statement.

Authors:  Sherita Hill Golden; Arleen Brown; Jane A Cauley; Marshall H Chin; Tiffany L Gary-Webb; Catherine Kim; Julie Ann Sosa; Anne E Sumner; Blair Anton
Journal:  J Clin Endocrinol Metab       Date:  2012-06-22       Impact factor: 5.958

Review 6.  Revisiting the seed and soil in cancer metastasis.

Authors:  Martin Mendoza; Chand Khanna
Journal:  Int J Biochem Cell Biol       Date:  2009-02-03       Impact factor: 5.085

7.  Prospective study of body mass index, physical activity and thyroid cancer.

Authors:  Michael F Leitzmann; Alina Brenner; Steven C Moore; Corinna Koebnick; Yikyung Park; Albert Hollenbeck; Arthur Schatzkin; Elaine Ron
Journal:  Int J Cancer       Date:  2010-06-15       Impact factor: 7.396

8.  Advances in cellular therapy for the treatment of thyroid cancer.

Authors:  Claudia Papewalis; Margret Ehlers; Matthias Schott
Journal:  J Oncol       Date:  2010-06-29       Impact factor: 4.375

9.  M2‑like tumour‑associated macrophage‑secreted IGF promotes thyroid cancer stemness and metastasis by activating the PI3K/AKT/mTOR pathway.

Authors:  Juan Lv; Chao Liu; Fu-Kun Chen; Zhi-Ping Feng; Li Jia; Peng-Jie Liu; Zhi-Xian Yang; Fei Hou; Zhi-Yong Deng
Journal:  Mol Med Rep       Date:  2021-06-29       Impact factor: 2.952

10.  Insulin-like growth factor 1 receptor (IGF1R) expression and survival in operable squamous-cell laryngeal cancer.

Authors:  Giannis Mountzios; Ioannis Kostopoulos; Vassiliki Kotoula; Ioanna Sfakianaki; Elena Fountzilas; Konstantinos Markou; Ilias Karasmanis; Sofia Leva; Nikolaos Angouridakis; Konstantinos Vlachtsis; Angelos Nikolaou; Ioannis Konstantinidis; George Fountzilas
Journal:  PLoS One       Date:  2013-01-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.